Keywords: India, Patent ruling, Pfizer, Sutent, Liver and kidney cancer, ipla, Natco
Another negative Indian patent ruling, this time for Pfizer's Sutent
Article | 08 October 2012
In yet another setback for research-based pharmaceutical companies, last week the Indian patent office revoked US drugs behemoth Pfizer's(NNYSE: ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
